Phase II randomized, double-blind, multi-center, parallel-group, placebo-controlled multiple-loading dose regimen study to assess the safety, efficacy and duration of response of AIN457 in patients with chronic plaque-type psoriasis.
Phase of Trial: Phase II
Latest Information Update: 12 May 2016
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals Corporation
- 12 May 2016 Results (pooled analysis of this and other nine studies, n = 3993) assessing safety of secukinumab published in the Journal of the American Academy of Dermatology.
- 29 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Oct 2009 New trial record.